Abstract:To evaluate if breast-conserving therapy achieved superior efficacy to modified radical mastectomy in patients with T1-2N1M0 breast cancer. 2776 women with T1-2N1M0 breast cancer treated from 1999 to 2013 were retrospectively reviewed. All had received lumpectomy or mastectomy and axillary lymph node dissection without neoadjuvant chemotherapy. The median age was 49 years. 2484 patients underwent modified radical mastectomy (MRM), 580 (23.3%) of them received postoperative RT (MRM + RT). 292 patients received breast-conserving surgery (BCT), all of them received postoperative RT. For the whole group, 92.7% of received postoperative chemotherapy and 4.9% received trastuzumab targeted therapy. Of the 2148 patients with ER and/or PR positive, 87.7% received hormonal therapy. Survival and recurrence rates were calculated by using the Kaplan-Meier method and compared by log-rank test. Multivariable analysis was estimated by using the Cox proportional hazards model. At a median follow-up of 59 months (range, 1-257 months), the 5-year overall survival (OS) of the BCT and MRM groups was 97.9% and 92.9% (p= 0.014), and the 5-year locoregional recurrence (LRR) was 2.3% vs 6.1% (p= 0.022). Of MRM group, the 5-year OS was 92.7% in MRM alone and 93.5% in MRM + RT (p = 0.037), and the 5-year LRR was 6.3% and 5.2%, respectively (p = 0.188). Furthermore, the 5-year OS of BCT group was significantly higher than that of MRM alone (p = 0.007), however there was no significant difference in OS between BCT and MRM + RT (P = 0.160). The 5-year LRR of BCT group was significantly lower than that of MRM alone (p = 0.016), but had no significant difference with MRM + RT (p = 0.094). Univariate analysis showed that age ≤ 60 years, tumor grade I-II, T1, luminal subtype, no lymph-vascular invasion, BCT, RT, chemotherapy and hormonal therapy were favorable factors of OS (P <0.05). Age > 60 years, tumor grade I-II, T1, one axillary lymph node metastasis, luminal subtype, BCT, RT and hormonal therapy were favorable factors of LRR (P <0.05). Multivariate analysis showed that age (p = 0.009), T stage (p <0.001), molecular subtype (p = 0.009) and chemotherapy (p <0.001) were independent prognostic factors for OS. RT (p = 0.054) and hormonal therapy (p = 0.063) had a trend to improve OS. Age (p = 0.034), T stage (p = 0.002), molecular subtype (p <0.001), RT (P = 0.001) and the number of positive axillary lymph node (P <0.001) were independent prognostic factors for LRR. The type of breast surgery had no significant effect on OS (p = 0.388) and LRR (p = 0.836). The type of breast surgery had no significant effect on the prognosis of patients with T1-2N1M0 breast cancer. Postoperative radiotherapy significantly reduces the risk of locoregional recurrence and might improve overall survival, suggesting that it may be required for majority of patients with mastectomy.

[Prognostic Value of Sequencing of Radiotherapy and Chemotherapy Following Breast-Conserving Surgery for Patients with Breast Cancer].

Timing of Chemotherapy and Radiotherapy Following Breast-Conserving Surgery for Early-Stage Breast Cancer: A Retrospective Analysis

[Prognosis and risk factors of 1 791 patients with breast cancer treated with breast-conserving surgery based on real-world data].

Radiotherapy May Play an Important Role in Improving the Efficacy of Breast-Conserving Therapy Compared with Mastectomy in Patients with T1-2N1M0 Breast Cancer

Impact of Adjuvant Chemotherapy on the Prognosis of Hormone Receptor Negative Breast Cancer with Residual Lymph Node Disease after Neoadjuvant Chemotherapy

Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?

The Impact of Disparate Subtypes of Breast Cancer and Response to Postoperative Radiation Therapy in Neoadjuvant Setting

Impact of Preoperative vs Postoperative Radiotherapy on Overall Survival of Locally Advanced Breast Cancer Patients

Sequential Vs Concurrent Adjuvant Chemotherapy for Operable Breast Cancer: A Meta-Analysis

Combination Impact Of Axillary Lymph Node Status And Biological Subtypes On Prognosis And Breast Conserving Surgery In Locally-Invasive Breast Cancer: A Real-World Study Of A Chinese Population

Sequential Vs Concurrent Adjuvant Chemotherapy of Anthracycline and Taxane for Operable Breast Cancer

Neoadjuvant Versus Adjuvant Chemotherapy with Taxanes and Anthracycline-Based Regimen: Which Leads to Better Outcome in Patients with Different Subtype Breast Cancer?

Better Predictive Value of Axillary Lymph Node (ALN) Status after Systemic Therapy for Operable HER2-overexpressing Breast Cancer: A Single-Institution Retrospective Study

[The Effects of Sequence of Radiotherapy and Chemotherapy on Prognosis of Patients with Early-Stage Extranodal NK/T Cell Lymphoma (nasal Type) and Its Individualized Application].

Outcome of breast-conservative therapy for early-stage breast cancer: a retrospective analysis

Disscussion and analysis of the effect of adjuvant radiotherapy after neoadjuvant chemotherapy for stage T1-2N1M0 breast cancer

Radiotherapy plays an important role in improving the survival outcome in patients with T1–2N1M0 breast cancer – a joint analysis of 4262 real world cases from two institutions

21-gene recurrence score in predicting the outcome of postoperative radiotherapy in T1-2N1 luminal breast cancer after breast-conserving surgery

[Side Effects of Adjuvant Chemotherapy and Radiotherapy Concurrently after Conservative Surgery for Breast Cancer].

The inconsistency of molecular subtypes between primary foci and metastatic axillary lymph nodes in Luminal A breast cancer patients among Chinese women, an indication for chemotherapy?

Effects of Concurrent Chemoradiotherapy and Sequential Radiotherapy and Chemotherapy on Progression-free Survival in Patients with Non-small Cell Lung Cancer